Comparison between Mifepristone and Ulipristal acetate as an alternative to surgical management of uterine fibroids (Leiomyoma) in symptomatic patients of reproductive age group in Asian population

Ashish R. Kale

doi:10.18203/2320-1770.ijrcog20175528

Authors

Ashish R. Kale Department of Obstetrics and Gynecology, Ashakiran Hospital and Asha IVF Centre, Pune, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20175528

Keywords:

Asian population, Mifepristone, Symptomatic fibroids, Ulipristal acetate

Abstract

Background: Present study was a randomised prospective observational study carried out at Ashakiran Hospital and IVF centre Pune, Maharashtra, India to evaluate the efficacy, safety, and quality of life by using Ulipristal acetate 10 mg and Mifepristone 25 mg daily doses to treat uterine fibroids of two subgroups involving fibroids <3 cm and fibroids 3 to 5 cm all are in reproductive age group with symptomatic in nature over 3 months.

Methods: A total number of 40 patients were recruited in the study of which they were divided into two groups according to the size of the fibroid as <3cm and 3-5cm as seen on transvaginal as well as transabdominal ultrasound. Further they were randomly assigned to either mifepristone or ulipristal orally with each category having 10 patients each to assess changes in fibroid size, in symptomatic pain reduction, menorrhagia and in quality of life.

Results: The 25-mg dosage of Mifepristone is shown to be a good and effective way of treatment in fibroids less than 3 cm in achieving 40% reduction in size and 50% reduction in menorrhagia as compared to Ulipristal 10 mg which acts better in other subgroup of size 3-5 cm of fibroids.

Conclusions: Still larger RCTs are needed to study the long-term benefits of these drugs.

Metrics

Metrics Loading ...

References

Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Women’s Health. 2014;6:95-114.

Purohit P, Vigneswaran K. Fibroids and Infertility. Current Obstet Gynecol Reports. 2016;5:81-8.

Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar S, Gupta D, Vollenhoven B. Uterine fibroids. Nat Rev Dis Primers. 2016;2:16043.

Sparic R, Mirkovic L, Malvasi A, Tinelli A. Epidemiology of uterine myomas: a review. Int J Fertility Sterility. 2016;9(4):424-35.

Sue W, Sarah SB. Radiological appearances of uterine fibroids. Indian J Radiol Imaging. 2009;19(3):222-31.

Levens ED, Wesley R, Premkumar A, Blocker W, Nieman LK. Magnetic resonance imaging and transvaginal ultrasound for determining fibroid burden: implications for clinical research. Am J Obstet Gynecol. 2009;200(5):537.

Aluwee SAZBS, Kato H, Zhou X, Hara T, Fujita H, Kanematsu M, et al. Magnetic resonance imaging of uterine fibroids: a preliminary investigation into the usefulness of 3D-rendered images for surgical planning. Springer Plus. 2015;4:384.

Purslow CE. Fibroid uterus with red degeneration and with early gestation. Proceedings of the Royal Society of Medicine. Obstet Gynecol Sect. 1914;7:300.

Al Ansari AA, Al Hail FA, Abboud E. Malignant transformation of uterine leiomyoma. Qatar Med J. 2012;2012(2):71-4.

Divakar H. Asymptomatic uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):643-54.

Ciarmela P, Ciavattini A, Giannubilo SR, Lamanna P, Fiorini R, Tranquilli AL, et al. Management of leiomyomas in perimenopausal women. Maturitas. 2014;78(3):168-73.

Han NL, Ong CL. Magnetic resonance-guided focused ultrasound surgery (MRgFUS) of uterine fibroids in Singapore. Ann Acad Med Singapore. 2014;43(11):550-8.

Song H, Lu D, Navaratnam K, Shi G. Aromatase inhibitors for uterine fibroids. Cochrane Database Syst Rev. 2013;(10):CD009505.

Murji A, Whitaker L, Chow TL, Sobel ML. Selective progesterone receptormodulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev. 2017;4:CD010770.

Arendas K, Leyland NA. Use of ulipristal acetate for the management of fibroid-related acute abnormal uterine bleeding. J Obstet Gynaecol Can. 2016;38(1):80-3.

Woźniak S, Szkodziak P, Czuczwar P. The effect of ulipristal acetate treatment on symptomatic uterine fibroids within 12-months follow-up. Przegla̜d Menopauzalny Menopause Rev. 2014;13(1):18-21.

Englund K, Blanck A, Gustavsson I, Lundkvist U, Sjöblom P, Norgren A. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab. 1998;83(11):4092-6.

Feng C, Meldrum S, Fiscella K. Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone. International J Gynaecol Obstet. 2010;109(2):121-4.

Bourdet TA, Luton D, Koskas M. Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence. Int J Women’s Health. 2015;7:321-330.

Kalampokas T, Kamath M, Boutas I. Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis. Gynecol Endocrinol. 2016;32(2):91-6.